- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02542371
Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
Studieöversikt
Detaljerad beskrivning
Detailed Description:
Patients with HIV have been shown to have increased atherosclerotic risk compared to age-matched controls, and this risk is thought to be related to increased systemic immune activation. Specifically, systemic immune activation may contribute to destabilizing coronary atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using single photon emission computed tomography, applied initially to a group of HIV-infected patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis will prompt subsequent study of three comparison groups, as above.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
HIV infected subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- known active opportunistic infection requiring ongoing medical therapy (not including Hepatitis B/C)
- CD4 count < 50 cells/mm3
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV infected subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of clean aorta/ coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV infected subjects with known subclinical atherosclerosis
HIV negative subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV negative subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of clean aorta/coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV negative subjects with known subclinical atherosclerosis
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Case-Control
- Tidsperspektiv: Tvärsnitt
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
HIV infected with known subclinical atherosclerosis
|
|
|
HIV infected without known subclinical atherosclerosis
|
|
|
Non-HIV infected with known subclinical atherosclerosis
|
|
|
Non-HIV infected without known subclinical atherosclerosis
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Aortic plaque burden and morphology on CCTA in HIV Patients
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Imaging assessments in the coronary vasculature in HIV patients
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta
Tidsram: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Steven Grinspoon, M.D., Massachusetts General Hospital
Publikationer och användbara länkar
Allmänna publikationer
- Toribio M, Wilks MQ, Hedgire S, Lu MT, Cetlin M, Wang M, Alhallak I, Durbin CG, White KS, Wallis Z, Schnittman SR, Stanley TL, El-Fakhri G, Lee H, Autissier P, Zanni MV, Williams KC, Grinspoon SK. Increased Macrophage-Specific Arterial Infiltration Relates to Noncalcified Plaque and Systemic Immune Activation in People With Human Immunodeficiency Virus. J Infect Dis. 2022 Nov 11;226(10):1823-1833. doi: 10.1093/infdis/jiac301.
- Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, Autissier P, Foldyna B, Stone L, Martin A, Cope F, Abbruzzese B, Brady T, Hoffmann U, Williams KC, El-Fakhri G, Grinspoon SK. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 Apr 15;215(8):1264-1269. doi: 10.1093/infdis/jix095.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2014P001832
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .